KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Assets Average for 10 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • Quarterly Assets Average changed 0.28% to $2.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, changed 0.28% year-over-year, with the annual reading at $2.3 billion for FY2025, 0.8% up from the prior year.
  • Assets Average hit $2.3 billion in Q4 2025 for CRISPR Therapeutics AG, up from $2.1 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $2.9 billion in Q3 2021 to a low of $1.9 billion in Q1 2021.
  • Historically, Assets Average has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
  • Biggest five-year swings in Assets Average: surged 136.51% in 2021 and later fell 17.53% in 2022.
  • Year by year, Assets Average stood at $2.8 billion in 2021, then dropped by 17.53% to $2.3 billion in 2022, then decreased by 6.09% to $2.2 billion in 2023, then grew by 4.21% to $2.2 billion in 2024, then increased by 0.28% to $2.3 billion in 2025.
  • Business Quant data shows Assets Average for CRSP at $2.3 billion in Q4 2025, $2.1 billion in Q3 2025, and $2.1 billion in Q2 2025.